Clinical trials: sponsored by AstraZeneca
Hyperkalaemia, Chronic Kidney Disease
Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study
This is an open-label, randomised study in participants with chronic kidney disease (CKD) treated for hyperkalaemia (HK) whilst in hospital.
- Trial name
- CONTINUITY (NCT05347693)
- Testing
- Sodium Zirconium Cyclosilicate (SZC), Local standard of care
- Where
- 28 sites in Belgium, France and 4 more
- Volunteers
- 186 people
- Sponsor
- AstraZeneca
ER+ Breast Cancer, Ovarian Cancer
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
This Phase 1b is a dose escalation, MTD expansion and cohort expansions study to assess the safety and tolerability of a combination of NAP with durvalumab in subjects with selected advanced or metastatic solid tumors.
- Conditions
- ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT03983954
- Testing
- Obinutuzumab, naptumomab estafenatox and durvalumab, Naptumomab estafenatox and durvalumab
- Where
- 9 sites in India, Israel
- Volunteers
- 120 people
- Sponsor
- NeoTX Therapeutics Ltd.
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
The goal of this adaptive, interventional study is to assess the efficacy and safety of osimertinib-based adaptive treatment based on ctDNA dynamic monitoring in locally advanced or metastatic EGFRm NSCLC participants with ctDNA…
- Trial name
- NCT07058519
- Testing
- Osimertinib-based adaptive treatment, Osimertinib 80 MG
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Shanghai Chest Hospital
HER2-positive Breast Cancer
Basket Study for Oligo-metastatic Breast Cancer
The study will include patients with HER2-positive breast cancer and 1- 3 distant metastatic lesions, all amenable for curative intervention. Patients will be stratified by prior therapy and ER expression.
- Trial name
- ANISE (NCT05982678)
- Testing
- Trastuzumab deruxtecan
- Where
- Netherlands
- Volunteers
- 72 people
- Sponsor
- The Netherlands Cancer Institute
Estrogen Receptor Positive Breast Cancer
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer
This is a two stage study, with an initial dose escalation phase I study and subsequent double blind randomised phase II controlled trial.
- Trial name
- FAKTION (NCT01992952)
- Testing
- AZD5363, Fulvestrant
- Where
- 21 sites in United Kingdom
- Volunteers
- 149 people
- Sponsor
- Velindre NHS Trust
Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease
A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.
The purpose of this study is to evaluate the safety, tolerability and the pharmacodynamics (PD) of AZD4144 following oral administration in participants with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney…
- Trial name
- NCT06675175
- Testing
- AZD4144
- Where
- 15 sites in United States, Bulgaria and 2 more
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Breast Neoplasms, Triple-Negative, Breast Neoplasm Malignant Female
Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)
A Phase I of Olaparib with Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (triple negative breast cancer) or Patient With Operated TNBC with Residual Disease.
- Conditions
- Breast Neoplasms, Triple-Negative, Breast Neoplasm Malignant Female, Radiotherapy Side Effect
- Trial name
- RadioPARP (NCT03109080)
- Testing
- Olaparib, Radiation therapy
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Institut Curie
Bleeding
A Multifaceted Intervention to Improve Bleeding Management Among Patients Using Oral Anticoagulants (IMPACT-BLEEDING)
Prospective, cluster randomized trial including expected 168 patients with chronic use of oral anticoagulation (OAC) suffering major bleeding.
- Trial name
- NCT06575517
- Sponsor
- AstraZeneca
RELATED REGISTRY SEARCH
HF Prevalence and Evolution of HF in DM II Patients at High Risk
This is an epidemiological, single-country, multicenter, 2-year prospective cohort study based on both primary and secondary data collection, which will include a representative sample of 300 eligible T2DM patients managed in…
- Trial name
- HF-LanDMark (NCT04482283)
- Where
- 10 sites in Greece
- Volunteers
- 245 people
- Sponsor
- AstraZeneca
Heart Failure
Real-world Dapagliflozin Experience in Patients With Heart Failure in Greece
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide. Despite advancements in treatment, a HF diagnosis still leads to significant morbidity and mortality.
- Trial name
- EVOLUTION-HF (NCT05635331)
- Where
- 16 sites in Greece
- Volunteers
- 257 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer (NSCLC) participants who had disease recurrence or progression during/after at least one…
- Trial name
- DESTINY-LUNG02 (NCT04644237)
- Testing
- Trastuzumab deruxtecan
- Where
- 50 sites in United States, Australia and 8 more
- Volunteers
- 152 people
- Sponsor
- Daiichi Sankyo
Small Cell Lung Cancer
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed…
- Trial name
- ADRIATIC (NCT03703297)
- Testing
- Durvalumab, Tremelimumab
- Where
- 183 sites in United States, Argentina and 17 more
- Volunteers
- 730 people
- Sponsor
- AstraZeneca
Bladder Cancer
Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC Patients
The analysis of cell-free tumor DNA (cfDNA) in plasma has emerged as a clinically relevant predictive and prognostic biomarker in several metastatic solid malignancies, and even now represents standard-of-care for prescription of…
- Trial name
- ALU (NCT04412070)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hopital Foch
Non Small Cell Lung Cancer
Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC
This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior…
- Trial name
- NCT02197234
- Testing
- Pharmacokinetic sampling - AZD9291, Simvastatin, AZD9291 tablet dosing
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
This is a 2 part study in patients with EGFRm+ non small cell lung cancer (NSCLC), whose disease has progressed on an EGFRm TKI, who are refractory or resistant to standard therapy.
- Trial name
- NCT02157883
- Testing
- Pharmacokinetic sampling, AZD9291, Itraconazole
- Where
- 16 sites in United States, Belgium and 4 more
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Asthma, Asthma in Children
Diagnostic and Translational Values of Point-of-care Blood Eosinophils and Exhaled Nitric Oxide (FeNO) in People Referred by Primary Care for Suspected Asthma
Asthma is characterised by episodic symptoms (attacks) caused by airway inflammation and decreased airflow to the lungs. It affects 10% of the Canadian population and is the most common chronic disease in childhood.
- Conditions
- Asthma, Asthma in Children, Diagnosis, Inflammation
- Trial name
- DIVE (NCT05992519)
- Testing
- ¸FeNO
- Where
- Canada
- Volunteers
- 123 people
- Sponsor
- Université de Sherbrooke
Coronary Artery Disease
DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury
Heart attacks are most commonly caused by rupture of fatty deposits (plaques) within the wall of heart blood vessels. It appears that this process can also frequently occur without causing any symptoms and these events likely…
- Trial name
- DIAMOND (NCT02110303)
- Testing
- Ticagrelor
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- University of Edinburgh
Breast Cancer, Non-small Cell Lung Carcinoma
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.
- Trial name
- NCT04042701
- Testing
- Trastuzumab deruxtecan (DS-8201a), Pembrolizumab
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 115 people
- Sponsor
- Daiichi Sankyo
Dyslipidemia
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia.
- Trial name
- PURSUIT (NCT06173570)
- Testing
- AZD0780
- Where
- 55 sites in United States, Canada and 6 more
- Volunteers
- 428 people
- Sponsor
- AstraZeneca
Asthma, Osteoporosis, Osteopenia
Long-term Effect of Steroid on Metabolic Diseases in Asthmatics
The goal of this retrospective/observational study is to compare the clinical outcomes between the high-cumulative-dose group and the low- cumulative-dose group of oral/inhaled corticosteroid in the long-term management of asthma…
- Conditions
- Asthma, Osteoporosis, Osteopenia, Osteoporosis Risk, Osteoporotic Fractures
- Trial name
- NCT06279078
- Testing
- Corticosteroid
- Where
- South Korea
- Volunteers
- 19,968 people
- Sponsor
- Ajou University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.